Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

Werter IM, Huijts CM, Lougheed SM, Hamberg P, Polee MB, Tascilar M, Los M, Haanen JBAG, Helgason HH, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 May;68(5):787-798. doi: 10.1007/s00262-019-02313-z. Epub 2019 Feb 11.

PMID:
30756132
2.

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

Huijts CM, Lougheed SM, Bodalal Z, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Mar;68(3):503-515. doi: 10.1007/s00262-018-2288-8. Epub 2019 Jan 17.

3.

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

Huijts CM, Werter IM, Lougheed SM, Goedegebuure RS, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.

Cancer Immunol Immunother. 2019 Feb;68(2):319-329. doi: 10.1007/s00262-018-2248-3. Epub 2018 Nov 9.

4.

The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer.

Schneiders FL, Huijts CM, Reijm M, Bontkes HJ, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Immunobiology. 2018 Feb;223(2):171-177. doi: 10.1016/j.imbio.2017.10.029. Epub 2017 Oct 16.

PMID:
29055564
5.

Immunological effects of everolimus in patients with metastatic renal cell cancer.

Huijts CM, Santegoets SJ, de Jong TD, Verheul HM, de Gruijl TD, van der Vliet HJ.

Int J Immunopathol Pharmacol. 2017 Dec;30(4):341-352. doi: 10.1177/0394632017734459. Epub 2017 Oct 9.

6.

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer.

Labots M, Gotink KJ, Dekker H, Azijli K, van der Mijn JC, Huijts CM, Piersma SR, Jiménez CR, Verheul HM.

Exp Mol Med. 2016 Dec 16;48(12):e279. doi: 10.1038/emm.2016.114.

7.

Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.

Huijts CM, Santegoets SJ, Quiles Del Rey M, de Haas RR, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2016 Jul;168:47-54. doi: 10.1016/j.clim.2016.05.005. Epub 2016 May 14.

8.

Response to Comment on "mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells".

Huijts CM, de Gruijl TD, van der Vliet HJ.

J Immunol. 2015 Dec 1;195(11):5101-2. doi: 10.4049/jimmunol.1502170. No abstract available.

9.

mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells.

Huijts CM, Schneiders FL, Garcia-Vallejo JJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

J Immunol. 2015 Sep 1;195(5):2038-45. doi: 10.4049/jimmunol.1402710. Epub 2015 Aug 3.

10.

Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate.

Korangath P, Teo WW, Sadik H, Han L, Mori N, Huijts CM, Wildes F, Bharti S, Zhang Z, Santa-Maria CA, Tsai H, Dang CV, Stearns V, Bhujwalla ZM, Sukumar S.

Clin Cancer Res. 2015 Jul 15;21(14):3263-73. doi: 10.1158/1078-0432.CCR-14-1200. Epub 2015 Mar 26.

11.

Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.

Schneiders FL, Huijts CM, Mantici A, Menks MA, Scotet E, Veerhuis R, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2015 May;158(1):92-9. doi: 10.1016/j.clim.2015.03.007. Epub 2015 Mar 18.

PMID:
25796193
12.

Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.

Avan A, Adema AD, Hoebe EK, Huijts CM, Avan A, Veal GJ, Ruijtenbeek R, Wosikowski K, Peters GJ.

Curr Drug Targets. 2014;15(14):1312-21.

PMID:
25382189
13.

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.

Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, Verheul HM, van der Vliet HJ.

BMC Cancer. 2011 Nov 30;11:505. doi: 10.1186/1471-2407-11-505.

Supplemental Content

Loading ...
Support Center